

Patent
Attorney's Docket No. 033285-010

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
Istvan SZELENYI et al.)	Group Art Unit: Unassigned
Application No.: 10/089,449)	Examiner: Unassigned
Int'l. Filing Date: September 26, 2000)	Confirmation No.: 9422
For: NOVEL COMBINATION OF)	
LOTEPREDNOL AND β_2 -)	
ADRENOCEPTOR AGONISTS)	

INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,
BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By: 
Teresa Stanek Rea
Registration No. 30,427

Date: June 28, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Istvan SZELENYI et al.)	Group Art Unit: Unassigned
)	
Application No.: 10/889,449)	Examiner: Unassigned
)	
Int'l. Filing Date: September 26, 2000)	Confirmation No.: 9422
)	
For: NOVEL COMBINATION OF)	
LOTEPREDNOL AND β_2 -)	
ADRENOCEPTOR AGONISTS)	
)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or statement is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____

Teresa Stanek Rea
Registration No. 30,427

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: June 28, 2002

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.
033285-010

APPLICATION NO.
10/089,449

APPLICANT
Istvan SZELENYI et al.

INT'L. FILING DATE
September 26, 2000

GROUP
Unassigned

U.S. PATENT DOCUMENTS

Examiner Initials	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
	Number	Kind Code (if known)		

FOREIGN PATENT DOCUMENTS

Examiner Initials	Foreign Patent Document		Country	Date of Publication (MM-DD-YYYY)	Translation	
	Number	Kind Code (if known)			Yes	no

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	S. Nobel, et al., "Loteprednol Etabonate, Clinical Potential in the Management of Ocular Inflammation", Adis Drug Evaluation, October 1998, pp. 329-339 ✓		
	M. Palmqvist, et al., "Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist", Medline (R), 1992 ✓		
	S.P. Clissold, et al., "Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis", Medline (R), 1984 ✓		
	R.J. Shaw, "Pharmacology of fluticasone propionate", Medline (R), 1994 ✓		
	P.J. Barnes, et al., "Efficacy and safety of inhaled corticosteroids. New developments", Medline (R), 1998, Part A ✓		
Examiner Signature		Date Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.